CD19 and lymphoma: CART19 has shown remarkable and reproducible success in clinical trials for patients with B-cell leukemia and lymphoma and four FDA approved CD19-targeted CAR T-cell therapies are approved to date: (in order of first approval) tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel.